A negative feedback loop of H19/miR‐675/VDR mediates therapeutic effect of cucurmin in the treatment of glioma

Jiang, Pan; Chen, Tunan; Ma, Kang; Wang, Shi; Yang, Chen; Cui, Gaoyu

doi:10.1002/jcp.29127

Cited by 23 publications

(14 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As potential anticarcinogens, curcumin and its analogues have been explored for potential in regulating lncRNAs(Mishra et al 2019). For example, curcumin treats glioma by regulating the negative feedback loop of H19 / miR-675 / VDR (Pan et al 2020). Furthermore, Yoshida et al observed that curcumin reduced the resistance of pancreatic cancer cells to gemcitabine by inhibiting the expression of lncRNA PVT1 (Yoshida et al 2017).…”

Section: Discussionmentioning

confidence: 99%

The Curcumin Analog Da0324 Inhibits the Proliferation of Gastric Cancer Cells Via HOTAIRM1/miR-29b-1-5p/PHLPP1 Axis

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Our previous study has shown that Da0324, a curcumin analog, has significantly improved stability and antitumor activity. However, the molecular mechanisms of action of Da0324 remains poorly understood. Long non-coding RNA (lncRNA) has been certifed to play a key role in tumor progression. Here, we aim to investigate the molecular mechanisms underlying the anti-cancer activities of Da0324 through regulation of lncRNA HOTAIRM1. Methods Gastric cancer cell lines were treated with Da0324 and/or transfected with lentiviral vector expressing HOTAIRM1 shRNA, and/or miR-29b-1-5p mimics and/or small interference RNA (siRNA) against PHLPP1, or HOTAIRM1 siRNA or lentiviral vector expressing HOTAIRM1, as required. The expression of HOTAIRM1, miR-29b-1-5p and PHLPP1 in GC cells were determined by Real-Time PCR. Cell growth was examined by CCK-8 assay and colony formation assay in vitro. The targeted relationship between HOTAIRM1 and miR-29b-1-5p was verifed by luciferase reporter gene assay. Western blot was utilized to investigate PHLPP1 protein expression levels. Results Da0324 increased the expression of HOTAIRM1 in GC cells. HOTAIRM1 expression was significantly down-regulated in GC tissues, and the low expression of HOTAIRM1 was associated with the shorter survival rate of GC patients based on TCGA database. Knockdown of HOTAIRM1 promoted GC cell proliferation whereas overexpression of HOTAIRM1 inhibited GC cell proliferation as detected by CCK-8 and colony formation assays. Moreover, knockdown of HOTAIRM1 reversed the Da0324-mediated growth inhibition of GC cells. Furthermore, HOTAIRM1 acted as a sponge for miR-29b-1-5p and PHLPP1 is regulated by the HOTAIRM1/miR-29b-1-5p axis in GC cells. Overexpression of miR-29b-1-5p or knockdown of PHLPP1 reversed the ability of Da0324 to inhibit the growth of GC cells. Conclusions Our data suggest that Da0324 exerts antitumor activity by regulating HOTAIRM1/miR-29b-1-5p/PHLPP1 axis in GC cell, and provide new insights into the anti-cancer mechanism of Da0324.

show abstract

Section: Discussionmentioning

confidence: 99%

The Curcumin Analog Da0324 Inhibits the Proliferation of Gastric Cancer Cells Via HOTAIRM1/miR-29b-1-5p/PHLPP1 Axis

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…And, LINC00115 was shown to act as a key role in GSC selfrenewal and tumorigenicity by Tang et al (54) LINC00174 accelerated glycolysis and tumor progression by competitively binding with miR-152-3p in glioma, indicating this molecule might act as a molecular target for glioma diagnosis (55). LncRNA H19, which mediates the effect of curcumin in treating glioma accompanied by miR-675 and VDR, could act as a novel diagnostic biomarker (56). Li et al showed that LINC00645 could promote EMT, which was indispensable in the invasion and migration of glioma cells involving TGF-b by regulating the miR-205-3p-ZEB1 axis; thus, LINC00645 could be a prognostic indicator for glioma (57).…”

Section: Lncrnas As Diagnostic and Prognostic Biomarkers Of Gliomasmentioning

confidence: 99%

Roles of Long Noncoding RNAs in Conferring Glioma Progression and Treatment

2021

View full text Add to dashboard Cite

Accompanying the development of biomedicine, our knowledge of glioma, one of the most common primary intracranial carcinomas, is becoming more comprehensive. Unfortunately, patients with glioblastoma (GBM) still have a dismal prognosis and a high relapse rate, even with standard combination therapy, namely, surgical resection, postoperative radiotherapy and chemotherapy. The absence of validated biomarkers is responsible for the majority of these poor outcomes, and reliable therapeutic targets are indispensable for improving the prognosis of patients suffering from gliomas. Identification of both precise diagnostic and accurate prognostic markers and promising therapeutic targets has therefore attracted considerable attention from researchers. Encouragingly, accumulating evidence has demonstrated that long noncoding RNAs (lncRNAs) play important roles in the pathogenesis and oncogenesis of various categories of human tumors, including gliomas. Nevertheless, the underlying mechanisms by which lncRNAs regulate diverse biological behaviors of glioma cells, such as proliferation, invasion and migration, remain poorly understood. Consequently, this review builds on previous studies to further summarize the progress in the field of lncRNA regulation of gliomas over recent years and addresses the potential of lncRNAs as diagnostic and prognostic markers and therapeutic targets.

show abstract

“…H19 downregulation induced G0/G1 cell cycle arrest putatively via inhibiting the WNT/β-catenin signaling pathway ( 48 ). The oncogenic effects of H19 can be mediated via increased expression of miR-675 , which regulates expression of cadherin 13 ( 45 , 49 ) and vitamin D receptor (a transcriptional factor involved in several cell signaling pathways) ( 50 ). H19 also affects tumor proliferation through downregulating miR-152 ( 51 ) and upregulating tumor promoter inhibitor of apoptosis-stimulating protein of p53 (iASPP) via targeting miR-140 ( 52 ).…”

Section: Lncrnas In Gliomamentioning

confidence: 99%

Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review

Momtazmanesh

Rezaei

2021

Front. Oncol.

View full text Add to dashboard Cite

Glioma is the most common malignant central nervous system tumor with significant mortality and morbidity. Despite considerable advances, the exact molecular pathways involved in tumor progression are not fully elucidated, and patients commonly face a poor prognosis. Long non-coding RNAs (lncRNAs) have recently drawn extra attention for their potential roles in different types of cancer as well as non-malignant diseases. More than 200 lncRNAs have been reported to be associated with glioma. We aimed to assess the roles of the most investigated lncRNAs in different stages of tumor progression and the mediating molecular pathways in addition to their clinical applications. lncRNAs are involved in different stages of tumor formation, invasion, and progression, including regulating the cell cycle, apoptosis, autophagy, epithelial-to-mesenchymal transition, tumor stemness, angiogenesis, the integrity of the blood-tumor-brain barrier, tumor metabolism, and immunological responses. The well-known oncogenic lncRNAs, which are upregulated in glioma, are H19, HOTAIR, PVT1, UCA1, XIST, CRNDE, FOXD2-AS1, ANRIL, HOXA11-AS, TP73-AS1, and DANCR. On the other hand, MEG3, GAS5, CCASC2, and TUSC7 are tumor suppressor lncRNAs, which are downregulated. While most studies reported oncogenic effects for MALAT1, TUG1, and NEAT1, there are some controversies regarding these lncRNAs. Expression levels of lncRNAs can be associated with tumor grade, survival, treatment response (chemotherapy drugs or radiotherapy), and overall prognosis. Moreover, circulatory levels of lncRNAs, such as MALAT1, H19, HOTAIR, NEAT1, TUG1, GAS5, LINK-A, and TUSC7, can provide non-invasive diagnostic and prognostic tools. Modulation of expression of lncRNAs using antisense oligonucleotides can lead to novel therapeutics. Notably, a profound understanding of the underlying molecular pathways involved in the function of lncRNAs is required to develop novel therapeutic targets. More investigations with large sample sizes and increased focus on in-vivo models are required to expand our understanding of the potential roles and application of lncRNAs in glioma.

show abstract

A negative feedback loop of H19/miR‐675/VDR mediates therapeutic effect of cucurmin in the treatment of glioma

Cited by 23 publications

References 62 publications

The Curcumin Analog Da0324 Inhibits the Proliferation of Gastric Cancer Cells Via HOTAIRM1/miR-29b-1-5p/PHLPP1 Axis

The Curcumin Analog Da0324 Inhibits the Proliferation of Gastric Cancer Cells Via HOTAIRM1/miR-29b-1-5p/PHLPP1 Axis

Roles of Long Noncoding RNAs in Conferring Glioma Progression and Treatment

Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review

Contact Info

Product

Resources

About